American College of Cardiology recommends empagliflozin as pre...
INGELHEIM, Germany and INDIANAPOLIS, Ind., Nov. 27, 2018 /PRNewswire-AsiaNet/ -- A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type 2 diabetes...
Read more https://view-release/?pr-id=76494